Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
  1. Home
  2. Publications
  3. Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Authors:
  • KSKohei Shitara
    Kohei Shitara
  • MTMotohiro Tamiya
    Motohiro Tamiya
  • KOKyoichi Okishio
    Kyoichi Okishio
  • HHHisashi Hosaka
    Hisashi Hosaka
  • KSKatsunori Shinozaki
    Katsunori Shinozaki
  • Nobuhiko Seki
    Nobuhiko Seki
  • HHHiroki Hara
    Hiroki Hara
  • YNYukiya Narita
    Yukiya Narita
  • TSTakeshi Shiraishi
    Takeshi Shiraishi
  • YTYosuke Tamura
    Yosuke Tamura
  • ATAkihito Tsuji
    Akihito Tsuji
  • KTKunihiro Tsuji
    Kunihiro Tsuji

Open Access
Publisher website
Google Scholar
  • 15 October 2025
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2767-9764.30365786
Abstract
Representativeness of study participants
Keywords
  • BIOMARKERS FOR IMMUNOTHERAPY
  • CLINICAL TRIAL RESULTS
  • PHASE II CLINICAL TRIALS
  • CHECKPOINT BLOCKADE
  • GASTROINTESTINAL CANCERS
  • STOMACH CANCER
  • LUNG CANCER
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.